

PATENT  
ATTORNEY DOCKET: 59866.000002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of: )  
M. N. Holten-Andersen et al. ) Confirmation No.: 3408  
Serial No.: 09/546,573 ) Art Unit: 1642  
Filed: April 10, 2000 ) Examiner: S. L. Rawlings, Ph.D.

For: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES  
TYPE-1 (TIMP-1) AS A CANCER MARKER

**MAIL STOP AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**3<sup>RD</sup> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the documents cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Some of the attached documents were cited in the International Search Report dated February 18, 2004 issued in International Application PCT/DK03/00634, copy enclosed, which is listed on the attached form PTO-SB/08A.

Applicants respectfully point out that submission of the listed documents in this 3<sup>rd</sup> Supplemental Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this 3<sup>rd</sup> Supplemental Information Disclosure is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited document is enclosed. In considering the cited documents, it


may be noted by the Examiner that certain of the documents may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited documents. Any such markings were either present on the copies of the cited documents obtained by the associated individuals, or were made thereon during the study of the documents by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO-SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 CFR § 1.97(c), this 3<sup>rd</sup> Supplemental Information Disclosure is being filed after the first Office Action on the merits, but (i) before the mailing date of a final Office Action for the above-identified patent application; or ii) before the mailing date of a Notice of Allowance for the above-identified patent application. Accordingly, please charge the undersigned's Deposit Account No. 50-0206 for this 3<sup>rd</sup> Supplemental Information Disclosure in the amount of \$180.00 which is being submitted pursuant to 37 CFR §§ 1.17(p) and 1.97(c). However, if any additional fees are incurred upon the filing of this 3<sup>rd</sup> Supplemental Information Disclosure, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

A handwritten signature in black ink, appearing to read 'Stanislaus A. Aksman', written over a horizontal line.

By:

Stanislaus A. Aksman  
Registration No. 28,562

Dated: May 3, 2005

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

SAA/sac

